gilead hiv franchis stay strong lower fve
shorter window strong yescarta growth
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim jan
price data feb
rate updat feb
currenc amount express
methodolog valu compani
gilead sale line estim
bottom-lin perform rel line
estim exclud one-tim excess inventori
charg older hcv therapi harvoni cost sale
line record fourth quarter howev
drug letairi angina drug ranexa continu hepat
 pressur rel earli growth trajectori car-
therapi yescarta think gilead rapidli grow hiv
busi abl yield flat growth
gilead see yescarta use transplant center
launch extend europ manag
forecast lower forecast
lower long-term yescarta revenu expect
addit competit could make difficult
gilead rapidli gain share lower yescarta
hcv estim slightli rais oper
expens assumpt gilead prepar potenti
launch rheumatoid arthriti drug filgotinib nash
drug selonsertib expect slightli lower fair valu
estim still think share look under-valued
continu view gilead hiv hcv portfolio
emerg busi oncolog immunolog
arriv earli march expect see potenti late-
stage commercial-stag acquisit year gilead
hiv sale growth could begin slow
yescarta competit celgen liso-cel pois arriv
growth potenti opinion expect
import catalyst firm outlin
recent healthcar observ annual drug pipelin
report moat remain secur innov counter
price gener headwind acceler
descovi data pre-exposur prophylaxi expect
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
second quarter given cdc see million
 potenti benefit treatment gilead
patient truvada think
signific potenti refresh truvada prep
franchis also reach addit patient unit
state nash selonsertib data patient advanc
fibrosi cirrhosi two separ trial expect
first second quarter data posit gilead
estim potenti approv first half
follow potenti combin therapi approv
follow phase data second half
cautiou near-term selonsertib data bullish
gilead abil offer combin regimen long
run see least billion nash peak sale gilead
also expect rheumatoid arthriti data two trial
filgotinib first quarter bullish drug
abil compet jak inhibitor base data
initi phase studi ra howev fda file
indic depend manta safeti studi
expect may avail
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
